Effects of Dexmedetomidine on Delirium After Living Donor Renal Transplantation in Adult Patients

Tao Zhang1 site in 1 country100 target enrollmentMay 2015

ConditionsPostoperative Delirium After Living Donor Renal Transplantation

InterventionsDexmedetomidine Saline

DrugsDexmedetomidine Saline

Overview

Phase: Phase 4
Intervention: Dexmedetomidine
Conditions: Postoperative Delirium After Living Donor Renal Transplantation
Sponsor: Tao Zhang
Enrollment: 100
Locations: 1
Primary Endpoint: Postoperative Delirium
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Delirium, an acute change in mental status, is a serious medical complication among hospitalized patients. Syndrome of delirium involves agitation, sleep disturbance, affective disorders and cognitive disruptions.

One vulnerable period for developing delirium is in the postoperative days. Postoperative delirium often initiates a cascade of adverse consequences including an increase in length of stay and hospital costs, and greater mortality. The investigators have observed that the incidence of postoperative delirium in patients after renal transplantation is about 20-30% in our hospital.

Several studies have revealed that dexmedetomidine, as a widely used sedative during anesthesia, can decrease the incidence of postoperative delirium after cardiac surgery. The investigators aim to examine whether administration of dexmedetomidine can reduce postoperative delirium after living donor renal transplantation in adult patients.

Registry

clinicaltrials.gov

Start Date

May 2015

End Date

September 2019

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Tao Zhang

Responsible Party

Sponsor Investigator

Principal Investigator

Tao Zhang

First Affiliated Hospital, Sun Yat-Sen University

Eligibility Criteria

Inclusion Criteria

•age \> 17 and \< 60 years;
•American Society of Anesthesiology (ASA) I-III;
•admitted for living donor renal transplantation.

Exclusion Criteria

•Patients with a history of drug abuse;
•preoperative history of schizophrenia, epilepsy, parkinsonism, use of cholinesterase inhibitor, inability to communicate in the preoperative period (coma, profound dementia, or language barrier).